CY1118007T1 - Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων - Google Patents

Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων

Info

Publication number
CY1118007T1
CY1118007T1 CY20161100752T CY161100752T CY1118007T1 CY 1118007 T1 CY1118007 T1 CY 1118007T1 CY 20161100752 T CY20161100752 T CY 20161100752T CY 161100752 T CY161100752 T CY 161100752T CY 1118007 T1 CY1118007 T1 CY 1118007T1
Authority
CY
Cyprus
Prior art keywords
methods
subscribing
subscribers
subscribing subscribers
glp
Prior art date
Application number
CY20161100752T
Other languages
English (en)
Inventor
Mark A Bush
Mary Colleen O’NEILL
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38024051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118007(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CY1118007T1 publication Critical patent/CY1118007T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μεθόδους χορήγησης υπογλυκαιμικών μέσων και/ή αγωνιστών GLP-1.
CY20161100752T 2005-11-04 2016-07-29 Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων CY1118007T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73392005P 2005-11-04 2005-11-04
US74260005P 2005-12-06 2005-12-06
PCT/US2006/060508 WO2007056681A2 (en) 2005-11-04 2006-11-03 Methods for administering hypoglycemic agents

Publications (1)

Publication Number Publication Date
CY1118007T1 true CY1118007T1 (el) 2017-05-17

Family

ID=38024051

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100752T CY1118007T1 (el) 2005-11-04 2016-07-29 Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων

Country Status (13)

Country Link
US (4) US8202837B2 (el)
EP (2) EP1965823B1 (el)
JP (2) JP2009514900A (el)
CY (1) CY1118007T1 (el)
DK (1) DK1965823T3 (el)
ES (1) ES2586236T3 (el)
HR (1) HRP20160866T1 (el)
HU (2) HUE029798T2 (el)
LT (2) LT1965823T (el)
PL (1) PL1965823T3 (el)
PT (1) PT1965823T (el)
SI (1) SI1965823T1 (el)
WO (1) WO2007056681A2 (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072143A1 (en) 2002-02-27 2003-09-04 Pharmain, Ltd. Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
HUE029798T2 (en) 2005-11-04 2017-03-28 Glaxosmithkline Llc Methods of administering hypoglycemic agents
WO2007076371A2 (en) 2005-12-19 2007-07-05 Pharmain Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
CN102274557B (zh) 2006-08-09 2014-12-03 精达制药公司 渗透性递送系统和活塞组件
JO2945B1 (en) 2006-09-13 2016-03-15 سميث كلاين بيتشام كوربوريشن Methods of giving prolonged hypoglycemic agents
DK2157967T3 (da) 2007-04-23 2013-04-08 Intarcia Therapeutics Inc Suspensionsformuleringer af insulinotropiske peptider og anvendelser deraf
JP2010530962A (ja) * 2007-06-12 2010-09-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 血漿においてタンパク質を検出する方法
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
LT2373681T (lt) * 2008-12-10 2017-04-10 Glaxosmithkline Llc Albiglutido farmacinės kompozicijos
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
JP2013525491A (ja) 2010-05-04 2013-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 心血管障害を治療または予防し心血管保護を提供する方法
ES2791690T3 (es) 2011-02-09 2020-11-05 Glaxosmithkline Llc Formulaciones liofilizadas
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9926570B2 (en) * 2013-03-06 2018-03-27 Glaxosmithkline Llc Host cells and methods of use
CN105189465B (zh) 2013-03-21 2019-02-26 赛诺菲-安万特德国有限公司 合成含有乙内酰脲的肽产物
US10450343B2 (en) 2013-03-21 2019-10-22 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
WO2023179796A1 (en) * 2022-03-25 2023-09-28 Beijing Ql Biopharmaceutical Co., Ltd. Pharmaceutical compositions of polypeptide conjugates and methods of uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313439A (en) 1980-03-24 1982-02-02 Biotek, Inc. Automated, spring-powered medicament infusion system
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK134691D0 (da) 1991-07-12 1991-07-12 Novo Nordisk As Apparat
US5536249A (en) * 1994-03-09 1996-07-16 Visionary Medical Products, Inc. Pen-type injector with a microprocessor and blood characteristic monitor
US6629963B2 (en) * 1996-06-20 2003-10-07 Becton, Dickinson And Company Syringe and needle shield assembly and method of sterilizing such assembly
US6146361A (en) * 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
CA2341454A1 (en) * 1998-08-28 2000-03-09 Benjamin Lee Hughes Method for administering insulinotropic peptides
US20030087820A1 (en) 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
US6843781B2 (en) * 1999-10-14 2005-01-18 Becton, Dickinson And Company Intradermal needle
US6569143B2 (en) * 1999-10-14 2003-05-27 Becton, Dickinson And Company Method of intradermally injecting substances
US6776776B2 (en) * 1999-10-14 2004-08-17 Becton, Dickinson And Company Prefillable intradermal delivery device
BR0116024A (pt) * 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
MXPA03005135A (es) * 2000-12-13 2003-12-04 Lilly Co Eli Regimen de tratamiento cronico usando peptidos insulinotropicos similares al glucagon.
JP2005506956A (ja) * 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー 長時間作用性ｇｌｐ−１製剤
CN1363654A (zh) * 2001-07-19 2002-08-14 上海华谊生物技术有限公司 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
US7235063B2 (en) * 2001-08-21 2007-06-26 D'antonio Consultants International, Inc. Hypodermic injection system
HUP0501192A3 (en) * 2001-08-23 2006-06-28 Lilly Co Eli Glucagon-like peptide-1 analogs
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
EP1463751B1 (en) * 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003058203A2 (en) * 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
MY139059A (en) 2002-06-24 2009-08-28 Alza Corp Reusable, spring driven autoinjector
AU2003286472A1 (en) * 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
EP1589901A4 (en) 2002-12-20 2006-08-09 Generipharm Inc INTRACUTANEOUS INJECTION
WO2004060920A1 (en) * 2002-12-31 2004-07-22 Altus Pharmaceuticals Inc. Complexes of protein crystals and ionic polymers
DE602004031927D1 (de) 2003-02-04 2011-05-05 Novo Nordisk As Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
EA008831B1 (ru) 2003-06-12 2007-08-31 Эли Лилли Энд Компани Слитые белки аналогов glp-1
CA2550050A1 (en) * 2003-12-18 2005-06-30 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents
PL1729795T3 (pl) * 2004-02-09 2016-08-31 Human Genome Sciences Inc Białka fuzyjne albuminy
DK1753723T3 (da) * 2004-05-21 2008-10-20 Novartis Vaccines & Diagnostic Substituerede quinolinderivater som mitotiske kinesininhibitorer
US7076987B2 (en) * 2004-08-05 2006-07-18 Becton, Dickinson And Company Method of producing tapered or pointed cannula
KR101011081B1 (ko) 2005-05-13 2011-01-25 일라이 릴리 앤드 캄파니 Ｐｅｇ화된 ｇｌｐ-1 화합물
ES2399645T3 (es) 2005-06-06 2013-04-02 Camurus Ab Formulaciones de análogos de GLP-1
HUE029798T2 (en) 2005-11-04 2017-03-28 Glaxosmithkline Llc Methods of administering hypoglycemic agents
JO2945B1 (en) 2006-09-13 2016-03-15 سميث كلاين بيتشام كوربوريشن Methods of giving prolonged hypoglycemic agents

Also Published As

Publication number Publication date
EP1965823B1 (en) 2016-05-18
JP2009514900A (ja) 2009-04-09
LTPA2016032I1 (lt) 2016-12-12
WO2007056681A2 (en) 2007-05-18
EP1965823A4 (en) 2010-08-04
HUS1600047I1 (hu) 2017-01-30
JP2014159431A (ja) 2014-09-04
PT1965823T (pt) 2016-08-18
LT1965823T (lt) 2016-10-10
HUE029798T2 (en) 2017-03-28
US20130231282A1 (en) 2013-09-05
EP3095456A1 (en) 2016-11-23
SI1965823T1 (sl) 2016-09-30
WO2007056681A3 (en) 2008-04-10
PL1965823T3 (pl) 2017-08-31
US8202837B2 (en) 2012-06-19
US20130225489A1 (en) 2013-08-29
US20080254087A1 (en) 2008-10-16
EP1965823A2 (en) 2008-09-10
DK1965823T3 (en) 2016-08-22
US20160022781A1 (en) 2016-01-28
HRP20160866T1 (hr) 2016-10-07
ES2586236T3 (es) 2016-10-13

Similar Documents

Publication Publication Date Title
CY1118007T1 (el) Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων
CY1120994T1 (el) Καινοτομες συνθεσεις διαλυματος που περιεχουν κυτταρικο παραγοντα και χρηση αυτων για τη θεραπεια τραυματων
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
EA200602243A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
EA200500520A1 (ru) Пуриновые соединения и их применение в качестве лигандов каннабиноидных рецепторов
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
CY1111579T1 (el) Νεα συνδυασμενη χρηση μιας ενωσης σουλφοναμιδης (sulfonamide) στην θεραπεια του καρκινου
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
CY1115713T1 (el) Παραγωγα ακρυλαμιδιου ως αντιβιοτικοι παραγοντες
EA200802213A1 (ru) Способы лечения заболеваний крови
BRPI0615705A2 (pt) processo para preparar um composto, e, composto
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
EA200870019A1 (ru) Лактамовые соединения и способы их применения
EA201100689A1 (ru) N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA200970140A1 (ru) Производные и аналоги n-этилхинолонов и n-этилазахинолонов
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
EA200501430A1 (ru) Лиганды каннабиноидных рецепторов и их применение
EA200602242A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
CY1108321T1 (el) Καινοφανη παραγωγα δικαρβοξυλικου οξεος
EA200702567A1 (ru) Ингибиторы дипептидил пептидазы iv, основанные на пирролопиридине
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
EA200801220A1 (ru) 3-аминоциклопентанекарбоксамиды в качестве модуляторов хемокиновых рецепторов